AI layoffs, Apple antitrust talks, and pharma price fights: Litigation Tracker - Week of July 13
This week's tracker covers six material developments: a Meta AI-assisted layoff ruling, Apple DOJ settlement talks, Google's EU AdSense appeal, a $229 million Kioxia patent verdict, and pharma pricing settlements involving Caremark and Glenmark.
Coverage window: July 14-20, 2026. This week's material disputes moved from abstract policy into operating systems: AI-assisted layoff scoring, smartphone gatekeeping, search-ad contracts, chip error correction, pharmacy-benefit rebates, and generic-drug pricing. Six developments deserve a place on the active watch list.
At a glance
| Case | Sector | Current stage | Why it matters | Next milestone |
|---|---|---|---|---|
| 26 anonymous employees v. Meta Platforms | AI / employment | Emergency bid to pause layoffs denied; merits claims are headed to individual arbitration | Tests whether AI-assisted workforce scoring can create discrimination exposure when it uses productivity and AI-adoption signals | Layoffs begin for many workers on July 22; preliminary-injunction motion remains pending 1 |
| United States and 15 states v. Apple | Tech / antitrust | Early settlement discussions reported; no agreement announced | Any remedy could reshape access to iPhone features, app distribution, and payment interfaces | Whether the states join talks and whether Apple and DOJ reach a filed agreement 2 |
| Commission v. Google and Alphabet, C-826/24 P | Tech / antitrust | CJEU appeal hearing over a lower-court decision that annulled a EUR1.49 billion fine | Clarifies how the EU evaluates exclusive publisher contracts in search advertising | Court adviser's non-binding opinion due November 12; final ruling expected in the following months 3 |
| Viasat v. Kioxia | Tech / patents | Waco federal jury found infringement and awarded $229 million | Extends patent risk from satellite error-correction work into mainstream flash-memory devices | Post-verdict motions and any appeal; no date was reported 4 |
| FTC v. CVS Caremark | Pharma / drug pricing | Settlement announced in the FTC's insulin-pricing antitrust case | PBM rebate design is being treated as a direct patient-cost and access issue | Implementation of the agreed business-practice changes; the public report did not state a court date 5 |
| States v. Glenmark Pharmaceuticals | Pharma / generic pricing | Multistate price-fixing allegations resolved for $29.6 million | Shows that generic-drug competition remains exposed to coordinated-pricing claims a decade after the litigation began | Settlement administration; no public hearing date was reported 6 |
AI sector cases
Meta's AI-assisted layoff challenge survives its first emergency test
Parties. Twenty-six anonymous Meta employees sued Meta Platforms in the Northern District of California. They allege that AI-assisted tools helped rank and select workers for layoffs, with protected medical leave, family leave, disability, and pregnancy-related circumstances affecting the inputs. The complaint names systems that included Metamate, an employee-trained "second brain," productivity monitoring, and AI-token-usage dashboards. 7
Claims. The workers assert violations of the Family and Medical Leave Act, the Pregnancy Discrimination Act, the Americans with Disabilities Act, the Pregnant Workers Fairness Act, and related state and District of Columbia laws. Their theory is that the scoring process penalized employees whose output or AI-tool usage was reduced by protected leave or disability. Meta says workforce decisions were made by people, not AI. 1
Current stage. On July 17, U.S. District Judge William Orrick denied the employees' request to stop Meta from carrying out the layoffs while the underlying claims proceed in private arbitration. He held that the workers had not shown the irreparable harm required for emergency relief. The longer-lasting preliminary-injunction motion remains pending, and the judge said he could reconsider after receiving more evidence about how AI was used. 1
Business impact. The immediate risk is operational. Employers using automated or AI-assisted performance systems will need to preserve model inputs, audit leave and accommodation handling, and explain how human review changed the output. The case also highlights a recurring structural problem: the employees are proceeding individually in arbitration, while the alleged selection process was company-wide.
Precedent value. The order is not a ruling on discrimination or on whether Meta used AI unlawfully. Its significance is narrower and more useful for risk teams: a court may allow a disputed AI-assisted reduction in force to proceed while asking for more evidence before deciding whether the selection process supports emergency relief. The case is among the first reported challenges by workers at a major U.S. company to the alleged use of AI in layoffs.
Next milestone. Many of the layoffs are scheduled to be finalized on July 22, with others later in July or August. The pending preliminary-injunction motion, the arbitration process, and any evidence about the models' inputs will determine whether the case develops beyond an individual employment dispute.
Tech sector cases
Apple and DOJ explore a possible exit from the iPhone antitrust case
Parties. The U.S. Department of Justice and 15 states sued Apple in the U.S. federal court in Newark, New Jersey, in 2024. Reuters reported on July 17 that Apple and DOJ are in early settlement discussions, based on a Bloomberg News report. Reuters said it could not independently verify the report, and there is no guarantee of an agreement. 28
Claims. The government alleges that Apple monopolized the U.S. smartphone market, harmed smaller rivals, and raised prices through restrictions affecting super apps, cloud game streaming, messaging, smartwatches, and digital wallets. The complaint seeks changes to Apple's control over app distribution, contracts, and private software interfaces.
Current stage. This is a negotiation signal, not a settlement or a court ruling. Reuters reported that Apple has made multiple offers to DOJ, but it was not clear whether the state attorneys general were participating. The public report did not identify the terms of any offer.
Business impact. A negotiated remedy could be narrower than the government's original demand, but even a limited agreement could affect how Apple handles rival access to iPhone features, app distribution, and payment systems. Developers, device makers, and investors should treat the terms of any filed proposal as the relevant event, not the existence of talks alone.
Precedent value. The case is a direct test of whether a court or settlement can constrain a vertically integrated smartphone platform without dismantling the hardware-software model that produces its leverage. A resolution would sit alongside, rather than replace, the EU's Digital Markets Act obligations and other platform cases.
Next milestone. Watch for confirmation of the talks, participation by the state plaintiffs, or a proposed consent judgment. Until a filing appears, the remedy remains undefined.
Google asks the EU's top court to preserve its AdSense win
Parties. The European Commission is appealing a 2024 General Court decision that annulled a EUR1.49 billion fine against Google and Alphabet. The appeal, Commission v. Google and Alphabet, is C-826/24 P, before the Court of Justice of the European Union. 3
Claims. The Commission says Google used restrictive clauses in publisher contracts from 2006 to 2016 to prevent rivals from placing search advertisements on publisher websites, reinforcing Google's position in online search advertising. Google removed the clauses in 2016 and argues that the Commission's appeal overlooks evidence that rivals had meaningful opportunities to compete.
Current stage. At a July 15 hearing, Google's lawyer asked the CJEU to reject the Commission's appeal and uphold the General Court's decision. The lower court had found errors in the Commission's assessment. No final merits decision was issued this week.
Business impact. The case is about an older AdSense contract model, but the legal question reaches current ad-tech design. The Commission's position would make exclusive or restrictive publisher terms a central part of the dominance analysis; Google's position asks the court to give more weight to evidence of rival opportunity.
Precedent value. The ruling could clarify how the EU treats contractual restrictions in a market where the same company supplies both the advertising technology and the demand for publisher inventory. That is a more specific question than whether Google is generally dominant, and it may guide future cases involving platform contracts and ad intermediation.
Next milestone. A court adviser is due to issue a non-binding opinion on November 12. Reuters expects a final ruling in the following months.
Viasat wins a $229 million flash-memory patent verdict against Kioxia
Parties. Viasat sued Japanese chipmaker Kioxia in federal court in Waco, Texas. A federal jury found for Viasat on July 16. Viasat alleged that Kioxia's flash-memory devices used patented error-correction technology developed while Viasat was designing systems for satellites. Kioxia denied infringement and argued that the patent was invalid. 4
Claims. The patent covers technology intended to reduce power consumption and improve the reliability and longevity of computer memory. The dispute therefore turns on whether a technology developed for satellite communications reaches commercial flash-memory products and whether the patent survives validity challenges.
Current stage. The jury said Kioxia owes Viasat $229 million for infringement. The report did not state whether the verdict included a willfulness finding, enhanced damages, or an injunction. It is a jury verdict, not the end of the case.
Business impact. The award gives memory and storage companies another reminder that error-correction techniques can carry value outside the product category in which they were developed. Kioxia also faces a separate Viasat case involving Western Digital, so the dispute may create additional licensing and product-design pressure across the storage market.
Precedent value. The case does not announce a new patent rule on the available record. Its practical value lies in the way it connects specialized aerospace engineering to mass-market semiconductor components, a pattern that can make ownership and freedom-to-operate reviews harder for suppliers and downstream device companies.
Next milestone. Watch for post-trial motions, any request to alter the damages award, and an appeal. No further date was publicly reported.
Pharma and biotech cases
FTC settles insulin-pricing case with CVS Caremark
Parties. The Federal Trade Commission settled its lawsuit with CVS Caremark, a major U.S. pharmacy benefit manager owned by CVS Health. The action also concerned the broader PBM rebate structure involving Cigna's Express Scripts and UnitedHealth's Optum Rx. The FTC announced the Caremark settlement on July 14. 59
Claims. The FTC alleged that the PBMs' rebate practices favored insulin products with higher list prices and impeded access to the medicine, shifting costs to patients while generating financial benefits for the intermediaries. The settlement is with Caremark; it does not resolve the claims against every PBM named in the underlying theory.
Current stage. The case is resolved by settlement. Caremark must make changes to its dealings with employers, health plans, and pharmacies. The FTC said the agreement could save Americans up to $8.5 billion in out-of-pocket costs over ten years and unlock up to $4.5 billion in additional savings through pharmacy-counter rebates. Those are agency estimates, not adjudicated damages.
Business impact. PBMs now face litigation risk tied to the design of rebate flows, not only to the prices charged by drug manufacturers. Health plans, employers, and pharmacies will need to track whether the agreement changes contracting, rebate pass-through, or patient-facing pricing.
Precedent value. The settlement does not decide whether the FTC's legal theory would prevail at trial. It nevertheless gives the agency a concrete behavioral remedy in a market where list prices, rebates, and patient costs move in different directions. Other PBMs and drug manufacturers will be watching the implementation details more closely than the headline savings estimate.
Next milestone. Monitor the implementation of Caremark's required practice changes and the FTC's separate litigation involving other drug middlemen. The public reports did not state a court approval date.
Glenmark pays $29.6 million to resolve generic-drug price-fixing claims
Parties. Glenmark Pharmaceuticals agreed to pay $29.6 million to settle allegations brought by dozens of states. The states accused Glenmark of participating in a broad conspiracy to inflate and manipulate generic-drug prices and reduce competition. 6
Claims. The allegations sit inside multistate litigation that began about a decade ago and has targeted many generic manufacturers. Previous settlements cited by STAT included Lannett, Bausch, Apotex, and Heritage Pharmaceuticals, totaling $67 million.
Current stage. Glenmark's agreement resolves the claims against it for $29.6 million. The settlement is not a finding that Glenmark is liable, and the available report does not describe a trial ruling or admission of wrongdoing.
Business impact. Generic medicines account for roughly 90% of prescriptions written in the United States, so coordinated-pricing allegations can affect procurement, contracting, and compliance well beyond the named products. The duration of the litigation also shows how long pricing theories can remain a balance-sheet issue after the alleged conduct.
Precedent value. The agreement will not establish a new rule on parallel pricing or information exchange. Its value is cumulative: another resolution increases the pressure on generic manufacturers to preserve communications, review competitor contacts, and assess whether commercial coordination could be characterized as an agreement.
Next milestone. Watch the settlement administration and any further state resolutions in the generic-drug litigation. No public hearing date was reported.
Cases to watch
- X and major music publishers. X and a group of publishers including Universal Music Group and Sony Music asked courts in Tennessee and Texas to dismiss, with prejudice, both the publishers' copyright case and X's antitrust countersuit. The filings were reported on July 17, but the parties did not disclose whether they had reached a settlement or what licensing terms, if any, were agreed. 10
- The Google CJEU calendar. The November 12 court-adviser opinion in C-826/24 P is the next dated milestone in the AdSense appeal.
- Meta's July 22 layoffs. The treatment of the workers' preliminary-injunction motion and the evidence about AI use will determine whether this remains an arbitration-bound employment fight or becomes a broader test of automated workforce selection.
- Kioxia post-verdict procedure. The damages award will be easier to assess once the trial court addresses post-trial motions and any appeal.
- Pharma pricing enforcement. Caremark's implementation and the next generic-drug resolutions will show whether the current enforcement push produces repeatable conduct changes or a series of case-by-case payments.
References
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.